Financial Results, Quarterly Earnings Schedules, Marketing Authorizations, Completed Acquisitions, and New Drug Applications - Research Report on Johnson & Johnson, AbbVie, GSK, AstraZeneca, and Keryx

Editor Note: For more information about this release, please scroll to bottom.

Oct 18, 2013, 08:00 ET from Analysts' Corner

NEW YORK, October 18, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Johnson & Johnson (NYSE: JNJ), AbbVie Inc. (NYSE: ABBV), GlaxoSmithKline plc (NYSE: GSK), AstraZeneca PLC (NYSE: AZN), and Keryx Biopharmaceuticals Inc. (NASDAQ: KERX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Johnson & Johnson Research Report

On October 15, 2013, Johnson & Johnson released its Q3 2013 results. Johnson & Johnson registered sales of $17.6 billion in Q3 2013, up 3.1% YoY. Net earnings attributable to Johnson & Johnson were $3.0 billion in Q3 2013, up 0.5% YoY. The Company reported diluted EPS of $1.04 in Q3 2013, down 1.0% YoY. Commenting on the results, Alex Gorsky, Chairman and CEO of the Company, said, "Our third-quarter results reflect the solid, demonstrable results in achieving our near-term priorities while also advancing our longer term strategic growth drivers." Gorsky continued, "Our key products and successful new product launches delivered strong growth. We continue to progress our pipelines with a number of regulatory approvals, the submission of new drug applications, and execution of strategic collaborations. Our investments further strengthen our ability to deliver sustainable growth and bring meaningful innovations to patients and consumers." The Full Research Report on Johnson & Johnson - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: []


AbbVie Inc. Research Report

On October 4, 2013, AbbVie Inc. (AbbVie) announced that it will release its Q3 2013 results before the market opens on Friday, October 25, 2013. AbbVie reported that it will hold a live webcast of the quarterly earnings conference call on the same day at 8:00 a.m. CT (9:00 a.m. ET). The Company also informed that the live webcast can be accessed through its Investor Relations website, and the archived edition of the call will be available after 11:00 a.m. CT. The Full Research Report on AbbVie Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: []


GlaxoSmithKline plc Research Report

On October 4, 2013, GlaxoSmithKline plc (GSK) announced the submission of a variation to the Marketing Authorization to the European Medicines Agency (EMA), for the use of Arzerra (ofatumumab) in combination with an alkylator-based therapy for the treatment of CLL patients who have not received prior treatment and are inappropriate for fludarabine-based therapy. GSK reported that the submission is based primarily on results from an international, multi-centre, randomised Phase III study of ofatumumab in combination with chlorambucil versus chlorambucil alone in more than 400 patients with previously untreated CLL. The Full Research Report on GlaxoSmithKline plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: []


AstraZeneca PLC Research Report

On October 7, 2013, AstraZeneca PLC (AstraZeneca) announced that its global biologics research and development arm, MedImmune, completed the acquisition of Amplimmune on October 4, 2013. The Company said that MedImmune has acquired 100% of Amplimmune's shares for an initial consideration of $225 million and deferred consideration of up to $275 million based on reaching predetermined development milestones. AstraZeneca reported that the acquisition bolsters MedImmune's oncology pipeline by obtaining multiple early-stage assets for its immune-mediated cancer therapy (IMT-C) portfolio, including AMP-514, an anti-programmed cell death 1 (PD-1) monoclonal antibody. AstraZeneca also stated that other Amplimmune assets include multiple preclinical molecules targeting the B7 pathways. The Full Research Report on AstraZeneca PLC - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: []


Keryx Biopharmaceuticals Inc. Research Report

On October 8, 2013, Keryx Biopharmaceuticals Inc. (Keryx) announced that its New Drug Application (NDA) for Zerenex (ferric citrate coordination complex) has been accepted for filing by the US Food and Drug Administration (FDA). Ron Bentsur, CEO of Keryx, said, "We are very pleased with the FDA's acceptance for filing of our NDA for Zerenex, as this represents an important achievement in the development of Zerenex. We believe that Zerenex has the potential to make a meaningful difference in the lives of patients with chronic kidney disease on dialysis, and we look forward to continuing to work with the FDA in its review process of the Zerenex NDA." The Full Research Report on Keryx Biopharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: []



  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at
  5. For any urgent concerns or inquiries, please contact us at
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to for consideration.


Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.


Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.


Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts' Corner